Elsevier

Epilepsy & Behavior

Volume 22, Issue 4, December 2011, Pages 617-640
Epilepsy & Behavior

Review
The NMDA receptor complex as a therapeutic target in epilepsy: a review

https://doi.org/10.1016/j.yebeh.2011.07.024Get rights and content

Abstract

A substantial amount of research has shown that N-methyl-D-aspartate receptors (NMDARs) may play a key role in the pathophysiology of several neurological diseases, including epilepsy. Animal models of epilepsy and clinical studies demonstrate that NMDAR activity and expression can be altered in association with epilepsy and particularly in some specific seizure types. NMDAR antagonists have been shown to have antiepileptic effects in both clinical and preclinical studies. There is some evidence that conventional antiepileptic drugs may also affect NMDAR function. In this review, we describe the evidence for the involvement of NMDARs in the pathophysiology of epilepsy and provide an overview of NMDAR antagonists that have been investigated in clinical trials and animal models of epilepsy.

Highlights

► NMDAR function and expression are altered in epilepsy. ► NMDAR antagonists have antiepileptic effects in clinical and preclinical studies. ► NMDARs are involved in the mechanisms of action of some conventional anticonvulsant drugs.

Introduction

Epilepsy is one of the most common neurologic disorders encountered in clinical practice, affecting approximately 2 to 4 million people in the United States or 1 in 50 children and 1 in 100 adults [1]. Over the last two decades, a new generation of antiepileptic drugs (AEDs) has emerged for the pharmacological management of seizures. Concurrent with that development, the concept of optimum therapy for seizures has evolved to include complete control of seizures, absence of bothersome side effects, and an emphasis on maximizing quality of life [2]. However, the prospect of freedom from seizures and adverse effects remains elusive for a considerable number of patients with epilepsy despite concerted attempts by their physicians to utilize available pharmacotherapies to their full advantage. Approximately 25 to 30% of patients continue to suffer from seizures despite state-of-the-art treatment [3]. Epileptic syndromes that are in most cases resistant to therapy with conventional AEDs comprise, for example, Lennox–Gastaut syndrome, West syndrome, early myoclonic encephalopathy, myoclonic astatic seizures and severe myoclonic epilepsy in infancy [4]. The presence of bothersome side effects diminishes quality of life for many patients as well, suggesting the need for better tolerated AEDs.

It is well established that alterations in central inhibitory (e.g. γ-aminobutyric acid or GABA) and excitatory (e.g. glutamate) neurotransmission play a pivotal role in the etiology of epilepsy. It has been accepted that overstimulation of glutamatergic transmission and thereby activation of glutamate receptors may be of significant relevance for its clinical manifestations [5]. Among glutamate receptors, N-methyl-D-aspartate receptors (NMDARs) have been the focus of much basic and clinical research over the past two decades, producing an overwhelming body of evidence that blocking or suppressing NMDARs is effective in the prevention of and, in some cases, reversal of pathology in various models of neurological diseases, including epilepsy. The repertoire of NMDAR-targeted drugs in neurology is expected to grow in the near future. In this review we provide a brief overview of the rationale for the development of such drugs and then focus on NMDAR-targeted drugs currently used in the clinical setting and trials for the treatment of epilepsy as well as those evaluated in preclinical studies.

Section snippets

The NMDAR complex

Glutamate is the major excitatory neurotransmitter in the central nervous system (CNS) and acts on ionotropic and metabotropic glutamate receptors located at the presynaptic terminal and in the postsynaptic membrane at synapses in the brain and spinal cord. NMDARs are tetrameric structures of seven subunits including at least one copy of an obligatory subunit, NR1, and varying expression of a family of NR2 (NR2A-D) or NR3 (NR3A-B) subunits, with multiple binding sites including for glutamate,

NMDAR alteration in patients with epilepsy

Considering the fact that NMDAR activity plays a major role in neuronal excitation in the CNS, some investigators have evaluated the possible alterations of NMDARs in epilepsy, using a variety of methods such as assessment of subunit gene expression, immunoblotting, and binding affinities. Glutamatergic impulses from the entorhinal cortex constitute the major excitatory input to the hippocampus and a shift in glutamate-mediated excitability may be involved in the pathogenesis of epileptic

Overview of animal models of epilepsy

As summarized in Table 1, a wide variety of animal models of epilepsy and status epilepticus have been used to study potential anticonvulsants, including electrical stimulation models, chemoconvulsant-induced models (e.g. kainic acid (KA), pilocarpine, picrotoxin or bicuculline); physical models (e.g. hyperthermia, or photic or auditory stimulation), genetic models (e.g. mutant, transgenic or knockout) and spontaneous seizure models (e.g. post-kindling or post-chemoconvulsant). The maximal

Felbamate

Felbamate (Felbatol®) is a propanediol dicarbamate derivative (Fig. 2) which was synthesized in 1955 and submitted to the antiepileptic drug development program within the epilepsy branch of the National Institute of Neurological Disorders and Stroke in 1982 [45]. The mechanisms of action of felbamate have not been completely elucidated yet, though several have been suggested:

  • (a)

    Inhibition of voltage-sensitive Na+ or Ca2+ channels [46], [47].

  • (b)

    Potentiation of GABA-induced chloride currents [48],

Effects of conventional AEDs on NMDARs

Convergent evidence that NMDARs could be a valid target for developing novel targets for epilepsy also comes from reports indicating that a variety of AEDs of different classes (including carbamazepine, ethosuximide, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, topiramate and valproic acid) affect functioning and expression of NMDARs in different brain regions that are involved in several seizure types (Table 5). These results again support the hypothesis that combinations

A role for NMDARs in the bidirectional relationship between epilepsy and depression

Psychiatric comorbidities in epilepsy have been considered to reflect a “consequence or complication” [360]. Depression (along with anxiety) is one of the most frequent psychiatric comorbidities in epilepsy [361]. The prevalence of mood disorders in patients with epilepsy is 20–50%; the higher prevalence rates have been typically identified in patients with poorly controlled seizures [362]. Several studies have shown that lifetime risks of major depression in patients with chronic and

Adverse effects of NMDAR antagonists in clinical settings

Because glutamate is a major excitatory transmitter in the CNS, generalized inhibition of a glutamate receptor subtype such as the NMDAR causes adverse effects that could limit the potential for clinical applications. Therefore, while using NMDAR antagonists could be a potential therapeutic approach for controlling seizures, NMDAR antagonism is associated with an array of adverse effects. Both competitive NMDA and glycine antagonists, even although effective in preventing glutamate-mediated

Conclusion

During the last three decades, a large number of studies have indicated that the NMDAR complex is important in seizure phenomena, although more studies are clearly needed to demonstrate that pathology of NMDARs underlies epilepsy. Considering animal seizure models, NMDAR antagonists may be effective anticonvulsants. However, there is no compelling evidence to date that they are useful in the chronic treatment of human epilepsy. Some antagonists such as ketamine and magnesium sulfate should be

References (522)

  • R.S. Fisher

    Animal models of the epilepsies

    Brain Res Brain Res Rev

    (1989)
  • W. Loscher

    Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy

    Epilepsy Res

    (2002)
  • G.D. Pratt et al.

    Differential regulation of N-methyl-D-aspartate receptor subunit messenger RNAs in kindling-induced epileptogenesis

    Neuroscience

    (1993)
  • W.M. Al-Ghoul et al.

    Amygdala kindling alters N-methyl-D-aspartate receptor subunit messenger RNA expression in the rat supraoptic nucleus

    Neuroscience

    (1997)
  • P.J. Jensen et al.

    Cortical NMDAR-1 gene expression is rapidly upregulated after seizure

    Brain Res Mol Brain Res

    (1997)
  • J.E. Kraus et al.

    Regulation of alternative splicing of NMDAR1 in the kindling model

    Brain Res Mol Brain Res

    (1996)
  • A. Gerfin-Moser et al.

    Alterations in glutamate but not GABAA receptor subunit expression as a consequence of epileptiform activity in vitro

    Neuroscience

    (1995)
  • G.W. Mathern et al.

    Hippocampal AMPA and NMDA mRNA levels and subunit immunoreactivity in human temporal lobe epilepsy patients and a rodent model of chronic mesial limbic epilepsy

    Epilepsy Res

    (1998)
  • W. Lason et al.

    Effects of pilocarpine and kainate-induced seizures on N-methyl-D-aspartate receptor gene expression in the rat hippocampus

    Neuroscience

    (1997)
  • A.G. Chapman et al.

    Anticonvulsant effect of reduced NMDA receptor expression in audiogenic DBA/2 mice

    Epilepsy Res

    (1996)
  • R. Marianowski et al.

    N-Methyl-D-aspartate receptor subunits NR1 and NR2C are overexpressed in the inferior colliculus of audiogenic mice

    Neurosci Lett

    (1995)
  • M. Taglialatela et al.

    Felbamate inhibits cloned voltage-dependent Na+ channels from human and rat brain

    Eur J Pharmacol

    (1996)
  • T.P. Harty et al.

    Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit

    Epilepsy Res

    (2000)
  • M.L. Zupanc et al.

    Efficacy of felbamate in the treatment of intractable pediatric epilepsy

    Pediatr Neurol

    (2010)
  • S. Hanna et al.

    The syndrome of magnesium deficiency in man

    Lancet

    (1960)
  • H.D. Kruse et al.

    Studies on magnesium deficiency in animals. I. Symptomatology resulting from magnesium deprivation

    J Biol Chem

    (1932)
  • D.R. Buck et al.

    Effect of magnesium deficiency on nonspecific excitability level (NEL) and audiogenic seizure susceptibility

    Pharmacol Biochem Behav

    (1976)
  • M. Hallak et al.

    Peripheral magnesium sulfate enters the brain and increases the threshold for hippocampal seizures in rats

    Am J Obstet Gynecol

    (1992)
  • A. Ghasemi et al.

    Administration of lithium and magnesium chloride inhibited tolerance to the anticonvulsant effect of morphine on pentylenetetrazole-induced seizures in mice

    Epilepsy Behav

    (2010)
  • M.M. Safar et al.

    Magnesium supplementation enhances the anticonvulsant potential of valproate in pentylenetetrazol-treated rats

    Brain Res

    (2010)
  • D.B. Cotton et al.

    Central anticonvulsant effects of magnesium sulfate on N-methyl-D-aspartate-induced seizures

    Am J Obstet Gynecol

    (1993)
  • T.L. Turner et al.

    Magnesium therapy in neonatal tetany

    Lancet

    (1977)
  • E.L. Tso et al.

    Magnesium: clinical considerations

    J Emerg Med

    (1992)
  • L.P. Zou et al.

    Three-week combination treatment with ACTH + magnesium sulfate versus ACTH monotherapy for infantile spasms: a 24-week, randomized, open-label, follow-up study in China

    Clin Ther

    (2010)
  • Y. Sakakihara

    Treatment of West syndrome

    Brain Dev

    (2011)
  • B.M. Sibai et al.

    A comparison of intravenous and intramuscular magnesium sulfate regimens in preeclampsia

    Am J Obstet Gynecol

    (1984)
  • J.A. Pritchard et al.

    The Parkland Memorial Hospital protocol for treatment of eclampsia: evaluation of 245 cases

    Am J Obstet Gynecol

    (1984)
  • J.M. McCubbin et al.

    Cardiopulmonary arrest due to acute maternal hypermagnesaemia

    Lancet

    (1981)
  • G.C. Palmer et al.

    Preclinical profile of stereoisomers of the anticonvulsant remacemide in mice

    Epilepsy Res

    (1991)
  • M.A. Dichter et al.

    New antiepileptic drugs

    N Engl J Med

    (1996)
  • E.M. Urbanska et al.

    Excitatory amino acids in epilepsy

    Restor Neurol Neurosci

    (1998)
  • D.S. Carter et al.

    Characterization of spontaneous recurrent epileptiform discharges in hippocampal-entorhinal cortical slices prepared from chronic epileptic animals

    Seizure

    (2010)
  • B.S. Meldrum

    Excitotoxicity and selective neuronal loss in epilepsy

    Brain Pathol

    (1993)
  • T.A. Bayer et al.

    Hippocampal loss of N-methyl-D-aspartate receptor subunit 1 mRNA in chronic temporal lobe epilepsy

    Acta Neuropathol

    (1995)
  • G.W. Mathern et al.

    Human hippocampal AMPA and NMDA mRNA levels in temporal lobe epilepsy patients

    Brain

    (1997)
  • G.W. Mathern et al.

    Aberrant hippocampal mossy fiber sprouting correlates with greater NMDAR2 receptor staining

    Neuroreport

    (1996)
  • J.E. Franck et al.

    Physiologic and morphologic characteristics of granule cell circuitry in human epileptic hippocampus

    Epilepsia

    (1995)
  • G.W. Mathern et al.

    Hippocampal N-methyl-D-aspartate receptor subunit mRNA levels in temporal lobe epilepsy patients

    Ann Neurol

    (1999)
  • L. Neder et al.

    Glutamate NMDA receptor subunit R1 and GAD mRNA expression in human temporal lobe epilepsy

    Cell Mol Neurobiol

    (2002)
  • P.B. Crino et al.

    Differential expression of glutamate and GABA-A receptor subunit mRNA in cortical dysplasia

    Neurology

    (2001)
  • Cited by (0)

    View full text